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ABSTRACT
Candida spp. are an important cause of nosocomial bloodstream infection (nBSI) and are associated with
signiﬁcant morbidity and mortality. An historical cohort study was performed to evaluate the clinical
course of 60 randomly selected adult patients with nBSIs caused by Candida spp. Patients with BSI
caused by Candida albicans (n = 38) and non-albicans spp. (n = 22) were compared with 80 patients with
Staphylococcus aureus BSI by serial systemic inﬂammatory response syndrome (SIRS) and APACHE II
scores. The patients had a mean age of 52 years, the length of hospital stay before BSI averaged 21 days,
and 57% of patients required care in an intensive care unit before BSI. The mean APACHE II score was
17 on the day of BSI, and 63% of BSIs were caused by C. albicans. Antifungal therapy within the ﬁrst 24 h
of onset of BSI was appropriate in 52% of patients. Septic shock occurred in 27% of patients, and severe
sepsis in an additional 8%. Overall mortality was 42%, and the 7-day mortality rate was 27%. The
inﬂammatory response and clinical course were similar for patients with BSI caused by C. albicans and
non-albicans spp. In univariate analysis, progression to septic shock was correlated with high overall
mortality, as was an APACHE II score >25 at the onset of BSI. In multivariate analysis, the APACHE II
score at the onset of BSI and a systemic inﬂammatory response independently predicted overall
mortality, but the 7-day mortality rate was only predicted independently by the APACHE II score.
Clinical course and mortality in patients with Candida BSI were predicted by systemic inﬂammatory
response and APACHE II score, but not by the infecting species.
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INTRODUCTION
Candida spp. are important causes of nosocomial
bloodstream infection (nBSI) [1], particularly
among patients in the intensive care unit (ICU).
These infections are associated with high rates of
morbidity and mortality [2–4]. The incidence of
nBSI caused by Candida spp. has risen ﬁve- to 10-
fold in the past 20 years. Currently, Candida spp.
are the fourth leading cause of nBSI in the USA
[5–8], and account for 8–15% of all hospital-
acquired BSI in recent series [5,8–10]. During the
last two decades, both the incidence of nosoco-
mial candidaemia and the proportion of blood-
stream infections caused by Candida spp. other
than Candida albicans have continued to increase
[8,10–14].
Triazoles are used widely for the treatment of
systemic Candida infections, and their efﬁcacy has
been documented for both prevention [15–18] and
treatment [19,20]. Since the 1990s, the use of
ﬂuconazole has increased substantially [14], and
concerns have been voiced that greater use could
lead to the selection of more resistant Candida spp.
Prophylactic use of ﬂuconazole in critical care
units has selected Candida krusei and Candida
glabrata, and resulted in outbreaks of infection
caused by these relatively resistant pathogens.
The present study was conducted to evaluate
the relationships between the inﬂammatory
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response, clinical course and outcome of nBSI
caused by Candida spp.
MATERIALS AND METHODS
Setting
The Virginia Commonwealth University Medical Center
(VCUMC) is a 750-bed tertiary care facility in Richmond,
VA, USA. The hospital houses nine ICUs, including paediatric
ICUs and a burns unit. Approximately 30 000 patients are
admitted annually.
Study design
The Surveillance and Control of Pathogens of Epidemiological
Importance (SCOPE) database [7] was used to identify all
patients at VCUMC with a diagnosis of BSI caused by Candida
spp. between 1 December 1998 and 31 May 2002. Patients were
considered to have BSI caused by Candida spp. if at least one
blood culture was positive for these organisms. Only mono-
microbial episodes of BSI were included, and BSI episodes that
represented relapses were excluded. However, second epi-
sodes occurring during separate hospital admissions were
included as separate cases. Clinical data and isolates were
collected concurrently by infection control practitioners using
a standard case report form. The data collected included age,
gender, location of the patient (ward vs. ICU), clinical service,
duration of hospitalisation before the onset of BSI, predispo-
sing clinical conditions and bloodstream pathogen. Predispo-
sing clinical conditions included neutropenia (deﬁned as an
absolute neutrophil count <500 ⁄ lL), peritoneal or haemodia-
lysis, and intravascular catheters (i.e., central lines, arterial
catheters, peripheral intravenous (IV) catheters). Sources of
secondary BSI were recorded when cultures obtained from
distant sites yielded the same pathogen. Adverse outcomes
that occurred during the hospital stay were recorded. The
clinical condition of each patient was classiﬁed according to
systemic inﬂammatory response syndrome (SIRS) criteria
(daily) and APACHE II score. Classiﬁcations were compared
between patients with BSI caused by C. albicans and non-
albicans species, as well as between patients with Candida BSI
and 80 patients with BSI caused by Staphylococcus aureus from a
previous study utilising the same methodology in a compar-
able patient population [21].
Deﬁnitions
The patients’ physiological conditions before the BSI and at the
onset of BSI were assessed using the APACHE II score [22].
The clinical condition of each patient during the BSI was
classiﬁed as SIRS, sepsis, severe sepsis or septic shock using
the criteria of the American College of Chest Physicians ⁄ Soci-
ety of Critical Care Medicine (ACCP ⁄ SCCM) [23]. SIRS was
deﬁned as two or more of the following: temperature >38C or
<36C; heart rate >90 beats ⁄min; respiratory rate >20 breaths ⁄
min or a PaCO2 <32 mmHg; white blood cell count
>12 · 109 ⁄L or <4 · 109 ⁄L, or the presence of >10% immature
neutrophils. Sepsis was deﬁned as SIRS associated with the
isolation of Candida from at least one blood culture. Sepsis with
the presence of hypotension or systemic manifestations of
hypoperfusion constituted severe sepsis. Septic shock was
deﬁned as sepsis associated with hypotension that was
unresponsive to IV ﬂuid challenge, or the need for dopamine
>5 lg ⁄kg ⁄min or any other vasopressor agent.
The presence of organ system failure was assessed using the
criteria of Fagon et al. [24] with minor modiﬁcations: respir-
atory failure was deﬁned as a FiO2 >0.4 needed for >3 days in
ventilated patients; cardiovascular failure as any need for
epinephrine or norepinephrine, or a need for dopamine
(>5 lg ⁄ kg ⁄min) to maintain systolic blood pressure
>90 mmHg; renal failure as decreased urine output
(<500 mL ⁄ 24 h) or an acute increase in serum creatinine level
>2.0 mg ⁄dL, or the requirement for acute dialysis or ultra-
ﬁltration; failure of the haematopoetic system as a platelet
count <100 · 109 ⁄L; and liver failure as serum bilirubin
>5 mg ⁄dL. The source of BSI was deﬁned according to criteria
published previously [7]. Antifungal therapy was considered
appropriate if the patient received an antifungal agent to
which the organism identiﬁed was susceptible.
Incidence
Admission data were collected between 1 January 1998 and 31
December 2001. Incidence rates were calculated as number of
BSIs ⁄ 10 000 hospital admissions.
Microbiological methods
Blood cultures were processed at the VCUMC. Identiﬁcation to
the species level was performed using standard microbiologi-
cal procedures. MICs were determined using Etests (AB
Biodisk, Piscataway, NJ, USA); this method has been shown
to have a high correlation with NCCLS methods [25]. Results
were conﬁrmed using the NCCLS microbroth dilution method
[26]. C. albicans ATCC 14053, C. krusei ATCC 14243 and
Candida parapsilosis ATCC 22019 were used as controls.
Statistical analysis
Results were expressed as a mean ± SD, or as a proportion of
the total number of patients or isolates. For continuous
variables, mean values were compared using two sample
t-tests for independent samples. Differences in proportions
were compared using a Chi-square test or Fisher’s Exact Test,
as appropriate. Mean values are reported ±SD. All tests of
signiﬁcance were two-tailed, with a set at 0.05. The Mann–
Whitney U-test was performed to test the equality of continu-
ous variables. Independent predictors of the outcome of BSI
were identiﬁed by means of stepwise logistic regression
analysis, with a limit for entering and removing variables at
0.05. All statistical analyses were done using SPSS software
(SPSS Inc., Chicago, IL, USA).
RESULTS
Study population and patient characteristics
During the studyperiod, 2080nBSIswere identiﬁed
at VCUMC. Of these, 415 (20%) clinically signiﬁ-
cant episodes of BSI were identiﬁed in paediatric
patients (aged £ 16 years). Of the remaining
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episodes, 197 monomicrobial episodes of BSI were
caused by Candida spp. From these, a sample of 60
patients (only one episodeperpatient)was selected
randomly for further analysis.
Patients included in the study had a mean age
of 52 ± 17.5 years (range 22–82 years); 55% were
female. Thirty-four (57%) hospital-acquired BSIs
occurred in the ICU setting. At the time of
diagnosis of BSI, the most common clinical servi-
ces were general surgery (26 patients, 43%),
internal medicine (22, 37%), and haematology ⁄
oncology (7, 12%).
Underlying conditions (recorded as the diag-
nosis on admission) were classiﬁed as trauma
(including burns) in 23 (38%) patients, followed
by gastrointestinal symptoms in nine (15%)
patients. Among the potential factors predispo-
sing to BSI, intravascular devices were the most
frequent. Central venous catheters were in place
in 53 (88%) patients, followed by peripheral IV
catheters in 12 (20%) patients and arterial cathe-
ters in 20 (33%) patients. Urinary catheters were
in place in 41 (68%) patients. In total, 23 (38%)
patients were receiving total parenteral nutrition.
Haemodialysis was needed before the onset of BSI
in 12 (20%) patients, while ventilatory support
was needed for 26 (43%) patients. Overall, 25
patients died during hospitalisation, i.e., a crude
mortality rate of 42%. The characteristics of the
study population did not differ signiﬁcantly from
the overall population of patients with Candida
BSI admitted to VCUMC during the study period.
Incidence
The hospital-wide incidence of BSI between 1998
and 2001 was 191 ⁄ 10 000 hospital admissions,
and the overall incidence of BSI caused by Candida
spp. was 16 ⁄ 10 000. When stratiﬁed by pathogen,
hospital-wide incidence rates of BSI caused by
Candida spp. varied between 8.5 and 0.4 ⁄ 10 000
admissions for C. albicans and C. krusei, respect-
ively (Table 1). Incidence rates increased signiﬁ-
cantly over time (8.8 in 1998 vs. 20.8 in 2001),
including those for both C. albicans (5.6 in 1998 vs.
11.6 in 2001) and non-albicans spp. (3.1 in 1998 vs.
9.1 in 2001).
Microbiological features
Among 2080 episodes of monomicrobial BSI that
occurred at VCUMC during the study period, 197
(9.5%) episodes were caused by Candida spp. Of
the 60 Candida isolates included in this study,
C. albicans was the most common, accounting for
38 (63%) of Candida BSIs, followed by C. parapsi-
losis (n = 9, 15%), and C. glabrata (n = 8, 13%).
These proportions were similar for the overall
population of patients with Candida BSI at
VCUMC (Table 1).
Median MICs of ﬂuconazole were 0.38 mg ⁄L
(range 0.09–256 mg ⁄L) for C. albicans, 64 mg ⁄L
(range 1.5–256 mg ⁄L) for C. glabrata, and
1.0 mg ⁄L (range 0.38–3.00 mg ⁄L) for C. parapsilo-
sis. NCCLS guidelines suggest a breakpoint of
64 mg ⁄L for resistance [26]. On this basis, the
frequency of resistance to ﬂuconazole was 11% in
C. albicans, 50% in C. glabrata, and 0% in C. para-
psilosis.
Clinical course
Overall mortality was 40% in patients with BSI
caused by C. albicans, and 45% in patients with
BSI caused by non-albicans spp. Among the non-
albicans BSI patients, crude mortality was lowest
(22%) for the nine C. parapsilosis cases, and
highest (75%) for the eight C. glabrata cases.
Nineteen (50%) C. albicans isolates were recov-
ered from patients in the ICU, compared with 15
(70%) non-albicans isolates (p 0.17). The mean
time from hospital admission to onset of BSI
averaged 26 days for C. albicans (range 6–56 days)
and 22 days for non-albicans spp. (range
3–80 days). No signiﬁcant seasonal patterns were
observed.
Fig. 1 shows the inﬂammatory response of
patients with Candida BSI over time, showing
the percentage of patients with SIRS, severe
sepsis, septic shock and those who died during
Table 1. Incidence and species distribution of Candida spp.
isolated from monomicrobial bloodstream infection (BSI)
in adult patients and the associated crude mortality (1998–
2002; study population and all patients with Candida BSI)
Organism (n, patients)
BSI incidence
(per 10 000
admissions)
Study subset
(n = 60)
All patients with
Candida BSI
(n = 197)
%
Mortality
(%) %
Mortality
(%)
Candida albicans (n = 38) 8.5 63.3 39.5 53.8 39.6
Candida glabrata (n = 8) 3.2 15.0 75.0 20.3 52.5
Candida tropicalis (n = 4) 1.9 13.3 25.0 12.2 40.0
Candida parapsilosis (n = 9) 1.6 6.7 22.0 10.2 33.0
Candida krusei (n = 1) 0.4 1.7 100.0 2.5 60.0
All Candida spp. 15.8 100.0 42.0 100.0 42.6
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the observation period. With regard to the entire
observation period, severe sepsis developed in
ﬁve (8%) patients with BSI caused by Candida
spp., and septic shock occurred in an additional
16 (27%) patients. When patients with BSI caused
by C. albicans were compared with those with BSI
caused by non-albicans spp., there were no signi-
ﬁcant differences between the two groups with
regard to initial or most severe inﬂammatory
response during the course of BSI. In addition, the
inﬂammatory response over time did not differ
signiﬁcantly, with maximum inﬂammatory re-
sponse being recorded 3–7 days after the ﬁrst
positive blood culture. End-organ dysfunctions or
hypoperfusion abnormalities were seen in 21
(35%) patients, the most common of which were
acute renal failure (n = 11, 18%) or altered mental
status (n = 10, 17%). Progression to septic shock
was correlated with high overall mortality (RR
4.1; p < 0.001), as was an APACHE II score of >25
at the onset of BSI (RR 4.8; p < 0.001).
Among patients with BSI caused by Candida
spp., 31 (52%) received appropriate treatment
(based on the MIC data) within 24 h of the onset
of BSI. While SIRS did not differ signiﬁcantly over
time, crude mortality was 52% among those who
were treated appropriately within 24 h, compared
with 31% among those who were not; however,
those who were treated appropriately were also
more severely ill (mean APACHE score 18 vs. 15).
Patients with BSI caused by C. albicans did not
differ signiﬁcantly from patients with BSI caused
by non-albicans spp. with regard to crude mortal-
ity rates (39% vs. 45% died, p 0.65). However,
when stratiﬁed by markers of severity of illness at
the onset of BSI, patients with high APACHE II
scores were at higher risk for mortality
(p < 0.001). Multivariate analysis showed that
overall mortality was predicted independently
by an APACHE II score of ‡25 at the onset of BSI
(RR 1.2; p 0.001; Table 2), and development of
severe sepsis or septic shock (RR 2.4; p 0.02).
Other variables tested, including C. albicans vs.
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Fig. 1. Systemic inﬂammatory response syndrome (SIRS) over time in patients with Candida bloodstream infection. The
ﬁgure shows the percentage of patients with SIRS, severe sepsis, septic shock and those who were deceased on a day-to-
day basis. Among SIRS patients, the number of SIRS criteria met is shown in the respective bar.
Table 2. Multivariate analysis for 7-day mortality and
hospital crude mortality in patients with Candida blood-
stream infection
7-day mortality Hospital mortality
p RR 95% CI p RR 95% CI
APACHE II score >25
on day of BSI
0.001 1.44 1.06–1.54 0.001 1.21 1.08–1.36
Severe sepsis or
septic shock
0.160 NS 0.022 2.37 1.13–4.96
Mechanical ventilation 0.942 NS 0.539 NS
Central venous catheter 0.212 NS 0.063 NS
Arterial line 0.831 NS 0.705 NS
Infection caused
by Candida glabrata
0.585 NS 0.667 NS
ICU stay 0.819 NS 0.218 NS
ICU, intensive care unit; NS, not signiﬁcant (variable not included in ﬁnal model).
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non-albicans spp., appropriate vs. inappropriate
antifungal therapy within 24 h, and all signiﬁcant
univariate risk-factors, did not inﬂuence outcome.
Mortality at 7 days after onset of BSI was predic-
ted independently only by the APACHE II score
at the onset of BSI (RR 1.5; p 0.001; Table 2).
Inﬂammatory response over time also correlat-
ed closely with the severity of the underlying
pathophysiological conditions (as measured by
APACHE II). Speciﬁcally, the clinical course was
worse in patients who had an APACHE II
score ‡ 25 at the onset of BSI (Fig. 2).
Compared with 80 patients with S. aureus BSI,
the inﬂammatory response 48 h before and
14 days after the onset of BSI did not differ
signiﬁcantly (Fig. 3); however, there was a trend
towards a more severe response in patients with
Candida BSI (p 0.061). Considering only survivors,
patients with Candida BSI had a prolonged inﬂam-
matory response that returned to baseline after an
average period of 9 days after the onset of BSI,
compared with 6 days in patients with S. aureus
BSI. If survivors with higher and lower APA-
CHE II scores (‡25 vs. <25 at onset of BSI) from
both groups were compared, this difference was
seen only for patients with an APACHE II score
<25, whereas in patients with more severe under-
lying conditions, the return to baseline took
10 days for patients with Candida BSI, and 14 days
for patients with S. aureus BSI.
DISCUSSION
Invasive Candida infection accounts for up to 15%
of all nosocomial infections in the ICU setting and
is associated with a mortality rate of 40–60%,
similar to that of septic shock [27,28]. Despite the
increasing rates and high mortality of Candida BSI,
this disease is frequently not recognised and is
often treated inadequately. The present study
aimed to deﬁne the systemic inﬂammatory
response involved and showed that 27% of
patients met the criteria for septic shock and
35% had end organ dysfunction, which are facts
that many clinicians may not have appreciated
fully. The 40% crude mortality rate was similar to
that reported previously in the USA [8], and the
7-day mortality rate of 27% has been used by
some workers to estimate the attributable mortal-
ity. Thus, this is a highly lethal infection. Never-
theless, half of the patients in the present study
did not receive an appropriate drug within the
ﬁrst 24 h. This corroborates the data of Ibrahim
et al. [29] and highlights the frequent absence of
recognition and appropriate early treatment of
candidaemia. In the present series, 24% of isolates
were resistant to ﬂuconazole. Only the APA-
CHE II score and progression to severe sepsis or
septic shock were statistically signiﬁcant by mul-
tivariate analysis. However, because of the small
number of patients in this series, neutropenia and
corticosteroid therapy were not included in the
analysis.
Fluconazole is used increasingly as the drug of
choice for most patients with C. albicans fungae-
mia [30,31] as blood isolates with reduced sus-
ceptibility to ﬂuconazole are very uncommon
[32,33]. Among >3500 bloodstream isolates ana-
lysed in multicentre series, only 1% had reduced
susceptibility to ﬂuconazole [13,32–37]. In the
present series the median MIC was 0.38 mg ⁄L
and 10% of C. albicans isolates (3 ⁄ 31) exhibited
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decreased susceptibility to ﬂuconazole. The
absence of antifungal treatment has also been
identiﬁed as a risk-factor for death in patients
with Candida BSI in both univariate and multiva-
riate analyses [38,39]. In the present series, there
was no difference in clinical course or outcome
between patients who received appropriate anti-
fungal therapy within 24 h of onset of BSI and
those who did not. The differences seen in the ﬁrst
days were most likely caused by the fact that
patients who were more severely ill before the
onset of BSI were also more likely to receive
antifungal agents as part of their therapy. In
addition, the present series may not have been
large enough to detect small differences.
S. aureus is one of the leading causes of com-
munity-acquired and nosocomial BSI, causing
considerable morbidity and mortality [40]. The
clinical course of S. aureus BSI is usually severe,
with crude mortality of 30–40% in several series
[8]. In the present analysis, the progression
to severe sepsis and septic shock showed no
association with the pathogen (Candida spp. vs.
S. aureus). Since the groups did not differ with
regard to the initial presentation, the most severe
presentation of inﬂammatory response within
14 days of detection, or the inﬂammatory re-
sponse over time, it seems that BSI caused by
Candida spp. is at least comparable to that caused
by S. aureus with regard to clinical course, inﬂam-
matory response and mortality.
Among patients with Candida BSI, no difference
in outcome was observed between patients with
BSI caused by C. albicans or non-albicans spp.
Again, the population investigated was relatively
small, so that minor differences may not have
reached statistical signiﬁcance. However, insigni-
ﬁcant variables were distributed almost equally,
and no trend could be seen for any of the
investigated variables that were not signiﬁcant.
Larger prospective studies will be necessary to
conﬁrm these results.
When inﬂammatory response over time was
compared between patients with BSI caused by
Candida spp. or S. aureus, the response in patients
with Candida BSI seemed, generally, to be more
severe. However, this difference was not consis-
tent if patients were stratiﬁed by severity of
underlying conditions, as measured by APA-
CHE II score at the onset of BSI, and did not
reach statistical signiﬁcance. Analysis of a larger
group of patients may be necessary to evaluate
this question in detail. In addition, SIRS may not
only measure the physiological response to BSI,
but is also likely to be affected by underlying
clinical conditions. In an analysis of a subset of
the NORASEPT II trial, Hadley et al. [41] found
that patients with Candida BSI had a higher rate of
complications over time when compared with
patients with bacterial BSI, but this analysis
included only three patients with Candida BSI.
Underlying clinical conditions seem to play a key
role in the clinical course of BSI and, although
difﬁcult, it is necessary to control this parameter
in order to reach valid conclusions concerning the
impact of the causative pathogen on clinical
course and outcome of BSI.
In summary, the clinical course in patients with
BSI caused by C. albicans is similar to that in
patients with BSI caused by non-albicans Candida
spp., and to that in patients with BSI caused by
S. aureus, and appears to be related more closely
to the underlying condition of the patients than it
is to the causative pathogen. Adverse outcome in
the present study was predicted independently
by a high APACHE II score at the onset of BSI,
and by the development of severe sepsis or septic
shock. This study conﬁrms that BSI caused by
Candida spp. has a high mortality rate and
initiates a severe inﬂammatory response, leading
to a clinical course comparable to that of S. aureus
BSI, but with even higher mortality. In addition,
Candida spp. seem to be under-appreciated as
aetiological agents of severe BSI, leading to
delayed recognition and inappropriate treatment.
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